AADI BIOSCIENCE, INC.00032Q104US00032Q104002/28/2025Non-Binding Advisory Vote on Golden Parachutes Proposal: To approve, on a non-binding, advisory basis, certain compensation that will or may become payable to our named executive officers in connection with the Divestiture.SECTION 14A SAY-ON-PAY VOTESISSUER987890FOR98789FOR ABIVAX SA00370M103US00370M103606/06/2025Please see Exhibit A of the Depositary Notice of Combined General Meeting for agenda item.SECTION 14A SAY-ON-PAY VOTESISSUER1250000FOR125000FOR ABIVAX SA00370M103US00370M103606/06/2025Please see Exhibit A of the Depositary Notice of Combined General Meeting for agenda item.SECTION 14A SAY-ON-PAY VOTESISSUER1250000FOR125000FOR ADAPTIVE BIOTECHNOLOGIES CORPORATION00650F109US00650F109306/10/2025To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement;SECTION 14A SAY-ON-PAY VOTESISSUER91830FOR9183FOR ADVERUM BIOTECHNOLOGIES, INC.00773U207US00773U207806/17/2025To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER673240FOR67324FOR AKERO THERAPEUTICS, INC00973Y108US00973Y108206/03/2025To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER434200FOR43420FOR ALNYLAM PHARMACEUTICALS, INC.02043Q107US02043Q107605/08/2025To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER102730FOR10273FOR ANI PHARMACEUTICALS, INC.00182C103US00182C103605/22/2025To approve the compensation of the Company's named executive officers, on a non-binding, advisory basis.SECTION 14A SAY-ON-PAY VOTESISSUER2269930FOR226993FOR ARCELLX, INC.03940C100US03940C100905/28/2025To approve, on an advisory basis, the compensation of the named executive officers identified in the 2024 Summary Compensation Table in the "Executive Compensation" section of the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1480310FOR148031FOR ARGENX SE04016X101US04016X101905/27/2025The 2024 remuneration reportSECTION 14A SAY-ON-PAY VOTESISSUER309400FOR30940FOR ASTRAZENECA PLC046353108US046353108904/11/2025To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2024SECTION 14A SAY-ON-PAY VOTESISSUER3123000FOR312300FOR AVADEL PHARMACEUTICALS PLCG29687103IE00BDGMC59407/30/2024To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER4782550FOR478255FOR AVITA MEDICAL, INC.05380C102US05380C102706/04/2025To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER10000FOR1000FOR AXOGEN, INC.05463X106US05463X106306/19/2025To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER14461170FOR1446117FOR AXOGEN, INC.05463X106US05463X106306/19/2025To recommend by a non-binding advisory vote the frequency of future non-binding advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER144611701 YEAR1446117FOR AXSOME THERAPEUTICS, INC.05464T104US05464T104306/06/2025To approve, by non-binding advisory vote, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER155300FOR15530FOR BEIGENE LTD07725L102US07725L102605/21/2025THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, be and is hereby approved.SECTION 14A SAY-ON-PAY VOTESISSUER120FOR12FOR BIOMARIN PHARMACEUTICAL INC.09061G101US09061G101305/20/2025To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER10893040FOR1089304FOR C4 THERAPEUTICS, INC.12529R107US12529R107706/18/2025To cast a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER59124850FOR5912485FOR CELCUITY INC.15102K100US15102K100705/13/2025To approve, by a non-binding and advisory vote, compensation of the named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER24325030FOR2432503FOR DELCATH SYSTEMS, INC.24661P807US24661P807705/15/2025To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement ("Proxy Statement").SECTION 14A SAY-ON-PAY VOTESISSUER2327220FOR232722FOR DENALI THERAPEUTICS INC.24823R105US24823R105906/03/2025Advisory vote on executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER1000000FOR100000FOR EDGEWISE THERAPEUTICS INC28036F105US28036F105706/13/2025Conduct an advisory vote on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER764930FOR76493FOR EDGEWISE THERAPEUTICS INC28036F105US28036F105706/13/2025Conduct an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER7649301 YEAR76493FOR ESSA PHARMA INC.29668H708CA29668H708503/05/2025The approval, on a non-binding, advisory basis, of the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER22620260FOR2262026FOR ESTABLISHMENT LABS HOLDINGS INC.G31249108VGG31249108405/23/2025To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4270FOR427FOR EVOLUS, INC.30052C107US30052C107106/05/2025Approval of, on an advisory basis, the compensation of Evolus' named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER9944990FOR994499FOR GERON CORPORATION374163103US374163103605/21/2025To approve, on an advisory basis, the compensation of our Named Executive Officers, as disclosed in our Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER24000000FOR2400000FOR HCA HEALTHCARE, INC.40412C101US40412C101804/24/2025Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER164000FOR16400FOR IMMUNOVANT INC45258J102US45258J102508/12/2024To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2519000FOR251900FOR INSMED INCORPORATED457669307US457669307505/15/2025An advisory vote on the 2024 compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3157720FOR315772FOR INSPIRE MEDICAL SYSTEMS, INC.457730109US457730109005/01/2025Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER366440FOR36644FOR INTEGRA LIFESCIENCES HOLDINGS CORP.457985208US457985208205/09/2025To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER10704230FOR1070423FOR IOVANCE BIOTHERAPEUTICS, INC.462260100US462260100706/10/2025To approve, by non-binding advisory vote, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER19069620FOR1906962FOR JAZZ PHARMACEUTICALS PLCG50871105IE00B4Q5ZN4707/25/2024To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1329170FOR132917FOR JAZZ PHARMACEUTICALS PLCG50871105IE00B4Q5ZN4707/25/2024To indicate, on a non-binding advisory basis, the preferred frequency of the advisory vote on the compensation of Jazz Pharmaceuticals plc's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER13291701 YEAR132917FOR KINIKSA PHARMACEUTICAL INTERNATIONAL PLCG52694109GB00BRXB0C0706/03/2025To approve, on an advisory (non-binding) basis, the Company's UK Statutory Directors' Annual Remuneration Report for the period ended December 31, 2024.SECTION 14A SAY-ON-PAY VOTESISSUER4645000FOR464500FOR KINIKSA PHARMACEUTICAL INTERNATIONAL PLCG52694109GB00BRXB0C0706/03/2025To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4645000FOR464500FOR KRYSTAL BIOTECH, INC.501147102US501147102705/16/2025Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.SECTION 14A SAY-ON-PAY VOTESISSUER2353960FOR235396FOR LIVANOVA PLCG5509L101GB00BYMT0J1906/11/2025Ordinary Resolution: To approve, on an advisory basis, the Company's compensation of its named executive officers (''US Say on Pay'').SECTION 14A SAY-ON-PAY VOTESISSUER1070400FOR107040FOR MADRIGAL PHARMACEUTICALS INC.558868105US558868105706/20/2025Advisory vote to approve executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER67860FOR6786FOR MADRIGAL PHARMACEUTICALS INC.558868105US558868105706/20/2025Advisory vote to approve the frequency of future advisory votes to approve executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER678601 YEAR6786FOR MEREO BIOPHARMA GROUP PLC589492107US589492107205/13/2025That the compensation of the Company's named executive officers be approved, on an advisory (non-binding) basis.SECTION 14A SAY-ON-PAY VOTESISSUER6869530FOR686953FOR MEREO BIOPHARMA GROUP PLC589492107US589492107205/13/2025That the frequency of future advisory votes on the compensation of the Company's named executive officers be approved, on an advisory (nonbinding) basis.SECTION 14A SAY-ON-PAY VOTESISSUER68695301 YEAR686953AGAINST MERUS N.V.N5749R100NL001160626405/21/2025Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3297790FOR329779FOR NOVOCURE LIMITEDG6674U108JE00BYSS4X4806/04/2025A non-binding advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER54516390FOR5451639FOR NURIX THERAPEUTICS, INC.67080M103US67080M103605/19/2025To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER23687190FOR2368719FOR NUVALENT, INC.670703107US670703107506/18/2025To approve, on an advisory basis, the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1943570FOR194357FOR ORGANOGENESIS HOLDINGS INC68621F102US68621F102106/23/2025Approval, on an advisory basis, of the compensation paid to our named executive officers, as disclosed in the Company's proxy statement for its 2025 annual meeting of shareholders.SECTION 14A SAY-ON-PAY VOTESISSUER124783510FOR12478351FOR ORTHOFIX MEDICAL INC.68752M108US68752M108006/18/2025Advisory and Non-Binding Vote to Approve Executive Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER6019250FOR601925FOR ORTHOPEDIATRICS CORP.68752L100US68752L100805/23/2025To approve, on an advisory basis, the resolution approving the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER450000FOR45000FOR PACIRA BIOSCIENCES, INC.695127100US695127100506/10/2025Approval, on an advisory basis, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER850000FOR85000FOR PACIRA BIOSCIENCES, INC.695127100US695127100506/10/2025Advisory vote to approve the frequency of future advisory votes to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER8500001 YEAR85000FOR PRAXIS PRECISION MEDICINES, INC.74006W207US74006W207006/26/2025To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2025 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.SECTION 14A SAY-ON-PAY VOTESISSUER12497400FOR1249740FOR REVOLUTION MEDICINES, INC.76155X100US76155X100006/26/2025To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER547840FOR54784FOR RIGEL PHARMACEUTICALS, INC.766559702US766559702405/22/2025To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER11256010FOR1125601FOR SANOFI80105N105US80105N105404/30/2025Approval of the components of the compensation paid or awarded in respect of the year ended December 31, 2024 to Frédéric Oudéa, Chairman of the BoardSECTION 14A SAY-ON-PAY VOTESISSUER2712180FOR271218FOR SANOFI80105N105US80105N105404/30/2025Approval of the components of the compensation paid or awarded in respect of the year ended December 31, 2024 to Paul Hudson, Chief Executive OfficerSECTION 14A SAY-ON-PAY VOTESISSUER2712180FOR271218FOR SAREPTA THERAPEUTICS, INC.803607100US803607100406/05/2025ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATIONSECTION 14A SAY-ON-PAY VOTESISSUER325800FOR32580FOR SCHOLAR ROCK HOLDING CORPORATION80706P103US80706P103005/22/2025To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER408030FOR40803FOR STAAR SURGICAL COMPANY852312305US852312305206/18/2025Non-binding advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER20934040FOR2093404FOR SURMODICS, INC.868873100US868873100408/13/2024Approve, in a non-binding advisory vote, certain compensation that may be paid or become payable to our named executive officers in connection with the merger.SECTION 14A SAY-ON-PAY VOTESISSUER7817770FOR781777FOR SURMODICS, INC.868873100US868873100402/06/2025Approve, in a non-binding advisory vote, the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER3940600FOR394060FOR SYNDAX PHARMACEUTICALS, INC87164F105US87164F105705/14/2025To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2025 proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER4777130FOR477713FOR TANDEM DIABETES CARE, INC.875372203US875372203705/21/2025To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3778070FOR377807FOR TANDEM DIABETES CARE, INC.875372203US875372203705/21/2025To approve, on a non-binding, advisory basis, the frequency of future stockholder advisory votes to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER37780701 YEAR377807FOR TECTONIC THERAPEUTIC, INC878972108US878972108606/06/2025Advisory approval of the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER168410FOR16841FOR TECTONIC THERAPEUTIC, INC878972108US878972108606/06/2025Advisory vote on the frequency of stockholder advisory votes on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1684101 YEAR16841FOR TEVA PHARMACEUTICAL INDUSTRIES LIMITED881624209US881624209806/05/2025To approve, on a non-binding advisory basis, the compensation for Teva's named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER2005000FOR200500FOR TG THERAPEUTICS, INC.88322Q108US88322Q108506/12/2025An advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER25744380FOR2574438FOR THE BEAUTY HEALTH COMPANY88331L108US88331L108906/12/2025Approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER2203360FOR220336FOR UNITED THERAPEUTICS CORPORATION91307C102US91307C102706/26/2025Advisory resolution to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER2446940FOR244694FOR VERACYTE, INC.92337F107US92337F107506/17/2025The approval, on a non-binding advisory basis, of the compensation of our named executive officers, as disclosed in our proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER6222700FOR622270FOR VERACYTE, INC.92337F107US92337F107506/17/2025The selection, on a non-binding advisory basis, whether future advisory votes on the compensation paid by us to our named executive officers should be held every one, two or three years.SECTION 14A SAY-ON-PAY VOTESISSUER62227001 YEAR622270FOR VERASTEM, INC.92337C203US92337C203505/22/2025To approve an advisory vote on the compensation of the named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER4399720FOR439972FOR VERICEL CORPORATION92346J108US92346J108804/30/2025To approve, on an advisory basis, the compensation of Vericel Corporation's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER36610FOR3661FOR